The results of this study demonstrated that an intratumoral injection with this engineered oncolytic virus promoted the tumor infiltration and activation of neoantigen-specific T cells and immune cells, as well as neoantigen presentation on tumor cells via the inhibition of PD-L1 by the secreted PD-L1 inhibitors, leading to the systemic rejection of both the treated tumor and distant tumors. Here, CD274 is linked to neoplasm.